- Home
- NVCT vs PMI Comparison
NVCT vs PMI Comparison
Compare NVCT & PMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NVCT | PMI |
|---|---|---|
| Founded | 2020 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.0M | 202.7M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | NVCT | PMI |
|---|---|---|
| Price | $7.49 | $0.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $13.50 | N/A |
| AVG Volume (30 Days) | 52.1K | ★ 159.2K |
| Earning Date | 05-05-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.55 | $0.92 |
| 52 Week High | $11.52 | $13.68 |
Technical Indicators
Market Signals| Indicator | NVCT | PMI |
|---|---|---|
| Relative Strength Index (RSI) | 34.64 | 37.80 |
| Support Level | $7.23 | N/A |
| Resistance Level | $8.46 | $1.37 |
| Average True Range (ATR) | 0.40 | 0.10 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 18.35 | 6.89 |
Price Performance
Historical ComparisonAbout NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
About PMI Picard Medical Inc.
Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing an implantable Total Artificial Heart. It is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including TAH. The TAH is an implantable system designed to assume the full function of a failed human heart in patients suffering from advanced heart failure.